News | Pharmaceuticals | February 07, 2017

GE Healthcare to Commercialize Rapiscan Agent Outside North America

Availability of Rapiscan worldwide will provide imaging for coronary artery disease in larger adult patient populations

GE Healthcare, Rapiscan stress imaging agent, North America, Rapidscan Pharma Solutions Inc.

February 7, 2017 — GE Healthcare’s Life Sciences business announced in January that it acquired Rapidscan Pharma Solutions Inc., which has the exclusive rights to produce and sell the pharmacological stress agent Rapiscan (regadenoson) in territories outside the U.S., Canada and Mexico. GE Healthcare will help bring improved access to Rapiscan, offering an alternative screening method for patients who are unable to undergo traditional cardiac stress imaging procedures.

Rapiscan is a European Medicines Agency (EMA)-approved selective coronary vasodilator, used as a pharmacological stress agent for radionuclide myocardial perfusion imaging (MPI) in adult patients. It is used in the diagnosis of coronary artery disease (CAD), the most common type of cardiovascular disease, accounting for over 680,000 deaths in Europe alone[1] .

While MPIs are most commonly performed after a patient has exercised, some patients at risk of CAD cannot exercise due to various conditions such as asthma and chronic obstructive pulmonary disease. Rapiscan reduces the risks[2] of MPI tests for these patients by stimulating a patient’s heart to bring on the effects of exercise.

GE Healthcare already distributes Rapiscan in the U.K. and Germany and will maintain existing supplier and distributor networks created by Rapidscan Pharma Solutions to expand its global reach. Its commercial rights will complement Astellas’ commercial distribution of regadenoson in the U.S., Canada, and Mexico.

For more information: www.gehealthcare.com

References

[1] European Society of Cardiology. European Cardiovascular Disease Statistics, 2012. https://www.escardio.org/static_file/Escardio/Press-media/press-releases/2013/EU-cardiovascular-disease-statistics-2012.pdf

[2] Cerqueira MD et al, on behalf of the ADVANCE MPI Trial Investigators. Effects of age, gender, obesity and diabetes on the efficacy and safety of the selective A2A agonist Rapiscan versus adenosine: integrated ADVANCE MPI trial results. J Am Coll Cardiol 2008; 1: 307-316.

[3] Rapidscan.Rapiscan: Information Memorandum. 2016; 4

Related Content

ACC, Haymarket Medical Education, HME, myCME, RightSTEPS initiative, prescribing behavior, chronic heart failure
News | Heart Failure| February 22, 2017
The American College of Cardiology (ACC), Haymarket Medical Education (HME) and myCME have joined forces to develop...
Children's Hospital Los Angeles, CHLA, Frank Ing, 3-D printed model, pulmonary artery

Pediatric interventional cardiologist Frank Ing, M.D., chief of the Division of Cardiology and co-director of the Heart Institute at Children’s Hospital Los Angeles. Photo courtesy of Children's Hospital Los Angeles.

Feature | 3-D Printing| February 22, 2017
When Children’s Hospital Los Angeles cardiologists found evidence that a portion of Nate Yamane’s pulmonary artery they...
coordinated heart attack care, Ontario STEMI Bypass Protocol, Canada
News | Cath Lab| February 22, 2017
Two new Ontario-wide heart attack protocols for paramedic services and emergency departments that aim to saves lives...
transradial approach, same-day cardiac procedures, radial access, $300 million annual savings, JACC Cardiovascular Interventions study
News | Radial Access| February 22, 2017
If hospitals can perform more transradial, same-day percutaneous coronary intervention (PCI), hospitals across the U.S...
Siemens Healthineers, Compressed Sensing technology, MRI, FDA approval, RSNA 2017
Technology | Magnetic Resonance Imaging (MRI)| February 21, 2017
Siemens Healthineers announced that the U.S. Food and Drug Administration (FDA) has cleared the company’s Compressed...
Technology | Radial Access| February 17, 2017
Medtronic plc announced that its coronary portfolio will now include the DxTerity Diagnostic Angiography Catheter line...
Sponsored Content | Videos | Inventory Management| February 17, 2017
The supplies you use in your cath lab are complex and very valuable.
GE Healthcare, GSI Xtream, FDA clearance, spectral CT, Revolution, RSNA 2017, SCCT
Technology | Computed Tomography (CT)| February 15, 2017
February 15, 2017 — GE Healthcare announced U.S.
Mercator MedSystems, DANCE trial data, ISET, LINC, Bullfrog Micro-Infusion Device
News | Peripheral Arterial Disease (PAD)| February 15, 2017
Mercator MedSystems announced that the national co-principal investigators of the company’s DANCE trial each presented...
Cardinal Health survey, hospital staff, supply chain management, quality of care
News | Inventory Management| February 15, 2017
Better hospital supply chain management leads to better quality of care and supports patient safety, according to a new...
Overlay Init